- Home
- JSPR vs CVM Comparison
JSPR vs CVM Comparison
Compare JSPR & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JSPR | CVM |
|---|---|---|
| Founded | 2018 | 1983 |
| Country | United States | United States |
| Employees | 22 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1M | 19.3M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | JSPR | CVM |
|---|---|---|
| Price | $0.83 | $1.59 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | 265.3K | ★ 680.2K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.62 | $0.89 |
| 52 Week High | $7.19 | $13.48 |
Technical Indicators
Market Signals| Indicator | JSPR | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 35.39 |
| Support Level | $0.62 | $0.89 |
| Resistance Level | $1.03 | $4.84 |
| Average True Range (ATR) | 0.07 | 0.34 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 18.09 | 28.26 |
Price Performance
Historical ComparisonAbout JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.